🇺🇸 Vancomycin IV in United States
35 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 35
Most-reported reactions
- Alanine Aminotransferase Increased — 6 reports (17.14%)
- Aspartate Aminotransferase Increased — 5 reports (14.29%)
- Red Man Syndrome — 4 reports (11.43%)
- Respiratory Failure — 4 reports (11.43%)
- Blood Creatinine Increased — 3 reports (8.57%)
- Hypotension — 3 reports (8.57%)
- Rash — 3 reports (8.57%)
- Renal Failure — 3 reports (8.57%)
- Acidosis — 2 reports (5.71%)
- Alopecia — 2 reports (5.71%)
Other Infectious Disease approved in United States
Frequently asked questions
Is Vancomycin IV approved in United States?
Vancomycin IV does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Vancomycin IV in United States?
Debiopharm International SA is the originator. The local marketing authorisation holder may differ — check the official source linked above.